Related Experiment Video
Updated: Feb 19, 2026
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.4K
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction.
Haruhiko Yamazaki1, Hiroyuki Iwasaki2, Toshinari Yamashita2
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan h.yamazaki0413@kcch.jp.
In Vivo (Athens, Greece)
|November 6, 2017
Summary
Nivolumab can cause thyroid dysfunction in non-small cell lung cancer patients. A higher total number of nivolumab doses may increase the risk of developing this side effect.
Area of Science:
- Oncology
- Endocrinology
- Immunotherapy
Background:
- Thyroid dysfunction is a known side effect of nivolumab therapy.
- This study investigates nivolumab-induced thyroid dysfunction in non-small cell lung cancer (NSCLC) patients.
Purpose of the Study:
- To determine the incidence of thyroid dysfunction after nivolumab administration in NSCLC patients.
- To identify risk factors associated with nivolumab-induced thyroid dysfunction.
Main Methods:
- Retrospective analysis of 82 NSCLC patients treated with nivolumab.
- Assessment of thyroid function before and after nivolumab treatment.
- Statistical analysis to identify risk factors.
Main Results:
- 19.5% incidence of thyroid dysfunction in patients with normal baseline thyroid function.
- No significant differences in sex, age, or nivolumab dose among affected patients.
- Higher total number of nivolumab doses was significantly associated with thyroid dysfunction (p=0.03).
Conclusions:
- The total number of nivolumab doses administered may be a risk factor for thyroid dysfunction.
- Further research is needed to confirm this finding and explore underlying mechanisms.
Related Concept Videos
01:24Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
01:20Synthesis and Regulation of Thyroid Hormones
8.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.2K
01:29Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
657
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
657
01:23The Thyroid Gland
7.9K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
7.9K